<DOC>
	<DOCNO>NCT03088358</DOCNO>
	<brief_summary>To evaluate influence therapy follow efficacy safety parameter different TeaRx dose group Enoxaparin group : - Total venous thromboembolic event ( VTE ) , include confirmed deep venous thrombosis ( DVT ) , nonfatal pulmonary embolism ( PE ) , total mortality - Incidence DVT ( total , proximal , distal ) - Incidence nonfatal PE - Incidence symptomatic VTE ( DVT , PE ) - VTE cause mortality - Non-VTE caused mortality - Incidence hemorrhagic complication - Incidence major clinically relevant non-major bleeding - Adverse event ( AEs ) serious adverse event ( SAEs ) subject complaint , physical examination , vital sign , laboratory result</brief_summary>
	<brief_title>Safety Efficacy TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin Venous Thromboembolic Events ( VTE ) Prevention Following Total Knee Replacement</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<criteria>Male female , age ≥ 18 year ; Planned total knee replacement surgery ; Signed informed consent form ; Willing comply protocol ; Willing use adequate contraception trial . Surgery acute fracture 4 week screen ; history septic inflammation joint ; prosthesis revision one leg miss History venous thrombosis location PE History heparin induce thrombocytopenia thrombocytopathy ; hemorrhagic diathesis History evident coagulopathy relative Congenital thrombophilia Bleeding within 6 month screen ; increase risk bleed BMI le 18,5 40 kg/m2 Systolic BP &gt; 180 mmHg and/or diastolic BP &gt; 110 mmHg register twice within 1530 minute Hb ≤ 10.5 g/dL female ≤ 11.5 g/dL male Platelets &lt; 100 000/mm3 Clinical significant abnormality APTT and/or INR GFR &lt; 30 ml/min/1.73 m2 ALT AST ≥ 2 x ULN total bilirubin ≥1,5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>